Journal: Clinical Science (London, England : 1979)

Article Title: IGFBP7 promotes endothelial cell repair in the recovery phase of acute lung injury

doi: 10.1042/CS20240179

Figure Lengend Snippet:

Article Snippet: Verteporfin (YAP1 inhibitor) , MCE , Cat# HY-B0146.

Techniques: Recombinant, SYBR Green Assay, CCK-8 Assay, Extraction, Proliferation Assay, Immunoprecipitation

Journal: Acta Ophthalmologica

Article Title: Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care

doi: 10.1111/aos.15148

Figure Lengend Snippet: Prioritization criteria in the allocation of remaining ampoules of verteporfin in the Netherlands

Article Snippet: Verteporfin is manufactured by a single manufacturer: Alcami Carolinas Corporation (Charleston, South Carolina, United States).

Techniques: Functional Assay, Tomography

Journal: Acta Ophthalmologica

Article Title: Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care

doi: 10.1111/aos.15148

Figure Lengend Snippet: Absolute number of patients treated with photodynamic therapy per year in the clinic of the respondent, both in the normal situation and during the verteporfin shortage

Article Snippet: Verteporfin is manufactured by a single manufacturer: Alcami Carolinas Corporation (Charleston, South Carolina, United States).

Techniques:

Journal: Acta Ophthalmologica

Article Title: Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care

doi: 10.1111/aos.15148

Figure Lengend Snippet: Percentage of patients treated with photodynamic therapy per disease, both in the normal situation and during the verteporfin shortage. These values were calculated by dividing the number of PDT‐treated patients by the number of referred patients per clinic and averaging these percentages. The absolute number of referrals is noted below the bars. AMD = age‐related macular degeneration; CSC = central serous chorioretinopathy; PCV = polypoidal choroidal vasculopathy; PDT = photodynamic therapy. [Colour figure can be viewed at wileyonlinelibrary.com ]

Article Snippet: Verteporfin is manufactured by a single manufacturer: Alcami Carolinas Corporation (Charleston, South Carolina, United States).

Techniques:

Journal: Molecular Medicine Reports

Article Title: COL1A1 expression induced by overexpression of both a 15-amino acid peptide from the fibrinogen domain of tenascin-X and integrin α11 in LX-2 cells

doi: 10.3892/mmr.2022.12846

Figure Lengend Snippet: Induction of COL1A1 expression by overexpression of both hTNX-FGFFFF and ITGA11 in addition to inhibitors. (A) Induction of COL1A1 expression by overexpression of both hTNX-FGFFFF and ITGA11 with a TGFBRI inhibitor (SB525334). DMSO (lanes 1, 2 and 3) and SB525334 (lane 3) were added to the culture medium (DMEM/0.5% FBS) after the transfection of expression plasmids for both hTNX-FGFFFF and ITGA11 in LX-2 cells (lanes 2 and 3). (B) Induction of COL1A1 expression by overexpression of both hTNX-FGFFFF and ITGA11 with a YAP inhibitor (verteporfin). DMSO (lanes 1, 2 and 3) and vertepofin (lane 3) were added to the culture medium (DMEM/0.5% FBS) after the transfection of expression plasmids for both hTNX-FGFFFF and ITGA11 in LX-2 cells (lanes 2 and 3). Subsequently, the cells were cultured followed by cell lysate extraction, RNA purification and reverse transcription-quantitative PCR. (A and B) The expression level of each gene [ ACTA2, COL1A1 and TGFB1 for (A) and ACTA2, COL1A1 and YAP1 for (B)] in the control (lane 1) was set to 1.0, and the relative expression level of each gene compared with that of the control (lane 1) is shown (n=3). Data are presented as the mean ± SD. *P<0.05, **P<0.01 vs. control (lane 1); ## P<0.01 vs. lane 2, one-way ANOVA with the Bonferroni post hoc test. COL1A1 , type I collagen α1 chain; TNX, tenascin-X; ITGA11, integrin α11; ACTA2 , α-smooth muscle actin; YAP, Yes-associated protein; hTNX-FGFFFF, GGLRIPFPRDCGEEM peptide from fibrinogen-related domain of human tenascin-X (hTNX-FG).

Article Snippet: To investigate the possible signaling pathway involved in the induction of COL1A1 expression by overexpression of both hTNX-FGFFFF and integrin α11 in LX-2 cells, a TGF-β receptor type 1 (TGFBRI) inhibitor (SB525334) (MedChemExpress) and a YAP inhibitor (verteporfin) (Cayman Chemical) were used.

Techniques: Expressing, Over Expression, Transfection, Cell Culture, Extraction, Purification, Reverse Transcription, Real-time Polymerase Chain Reaction, Control

Journal: Biomedicines

Article Title: Current Limitations and Recent Progress in Nanomedicine for Clinically Available Photodynamic Therapy

doi: 10.3390/biomedicines9010085

Figure Lengend Snippet: Recent outcomes of clinical trials with photosensitizers.

Article Snippet: Nanocarrier , Verteporfin , Dendrimer–fucoidan nanocomplex , Sensitive to glutathione-targeted P-selectin , 2020 , [ ] .

Techniques: Clinical Proteomics

Journal: Biomedicines

Article Title: Current Limitations and Recent Progress in Nanomedicine for Clinically Available Photodynamic Therapy

doi: 10.3390/biomedicines9010085

Figure Lengend Snippet: Recent advances in preclinical developments using nanomedicine for PDT.

Article Snippet: Nanocarrier , Verteporfin , Dendrimer–fucoidan nanocomplex , Sensitive to glutathione-targeted P-selectin , 2020 , [ ] .

Techniques: CRISPR, Modification, Irradiation

Journal: Pharmaceuticals

Article Title: Synergistic Effect of Combination of a Temoporfin-Based Photodynamic Therapy with Potassium Iodide or Antibacterial Agents on Oral Disease Pathogens In Vitro

doi: 10.3390/ph15040488

Figure Lengend Snippet: The test methods’ flow charts and outcomes of the temoporfin treatment. ( a ) The procedures for three PDT treatment methods. Values of MIC and MBC of temoporfin for A. actinomycetemcomitans and S. mutans were obtained by treatment method I ( b ), method II ( c ), and method III ( d ). The left tube figure represents MIC test; the right dish figure represents MBC test.

Article Snippet: Temoporfin (ChemScene, Monmouth Junction, NJ, USA) was dissolved in dimethyl sulfoxide (DMSO) as 100 mg/mL stock solutions and stored at −20 °C.

Techniques:

Journal: Pharmaceuticals

Article Title: Synergistic Effect of Combination of a Temoporfin-Based Photodynamic Therapy with Potassium Iodide or Antibacterial Agents on Oral Disease Pathogens In Vitro

doi: 10.3390/ph15040488

Figure Lengend Snippet: The kinetic growth curve of A. actinomycetemcomitans and S. mutans were inhibited by temoporfin in a dose-dependent manner instead of KI. A. actinomycetemcomitans were treated with temoporfin ( a ) and KI ( c ); similarly, S. mutans were treated with temoporfin ( b ) and KI ( d ). The symbols on the right side of the graphs indicate various temoporfin (µg/mL) and KI (mg/mL) doses. The blue line indicates vehicle treatment (control) in each graph.

Article Snippet: Temoporfin (ChemScene, Monmouth Junction, NJ, USA) was dissolved in dimethyl sulfoxide (DMSO) as 100 mg/mL stock solutions and stored at −20 °C.

Techniques: Control

Journal: Pharmaceuticals

Article Title: Synergistic Effect of Combination of a Temoporfin-Based Photodynamic Therapy with Potassium Iodide or Antibacterial Agents on Oral Disease Pathogens In Vitro

doi: 10.3390/ph15040488

Figure Lengend Snippet: The MIC/MBC of the oral pathogens after temoporfin and the combination of 1 mg/mL KI treatment under normoxic and hypoxic conditions.

Article Snippet: Temoporfin (ChemScene, Monmouth Junction, NJ, USA) was dissolved in dimethyl sulfoxide (DMSO) as 100 mg/mL stock solutions and stored at −20 °C.

Techniques: Bacteria

Journal: Pharmaceuticals

Article Title: Synergistic Effect of Combination of a Temoporfin-Based Photodynamic Therapy with Potassium Iodide or Antibacterial Agents on Oral Disease Pathogens In Vitro

doi: 10.3390/ph15040488

Figure Lengend Snippet: Synergistic effect of temoporfin combined with KI on L. acidophilus and L. paracasei. The OD600 values of bacteria after vehicle and 0.5−8 μg/mL temoporfin treatment for 24 h ( a ) and 0.25−4 mg/mL KI treatment for 24 h ( b ). The OD600 of L. acidophilus ( c ), and L. paracasei ( d ) after temoporfin and KI co-treatment for 24 h. CompuSyn report for L. acidophilus ( e ) and L. paracasei ( f ). * CI < 0.3.

Article Snippet: Temoporfin (ChemScene, Monmouth Junction, NJ, USA) was dissolved in dimethyl sulfoxide (DMSO) as 100 mg/mL stock solutions and stored at −20 °C.

Techniques: Bacteria

Journal: Pharmaceuticals

Article Title: Synergistic Effect of Combination of a Temoporfin-Based Photodynamic Therapy with Potassium Iodide or Antibacterial Agents on Oral Disease Pathogens In Vitro

doi: 10.3390/ph15040488

Figure Lengend Snippet: The combination of temoporfin with ampicillin or CHX inhibited MRSA growth. ( a ) The MRSA was treated with vehicle, temoporfin alone, ampicillin alone, and temoporfin and ampicillin co−treatment. ( b ) The MRSA was treated with vehicle, temoporfin alone, CHX alone, and temoporfin and CHX co−treatment. CompuSyn report for ampicillin ( c ) and CHX ( d ). ( e ) The antibiotic-resistant genes mecI , mecR1 , and mecA expression fold change in MRSA after temoporfin treatment for 24 h. * p < 0.05, ** p < 0.01, and *** p < 0.001 compare with vehicle ( e ). * CI < 0.05 ( c , d ).

Article Snippet: Temoporfin (ChemScene, Monmouth Junction, NJ, USA) was dissolved in dimethyl sulfoxide (DMSO) as 100 mg/mL stock solutions and stored at −20 °C.

Techniques: Expressing

Journal: Pharmaceuticals

Article Title: Synergistic Effect of Combination of a Temoporfin-Based Photodynamic Therapy with Potassium Iodide or Antibacterial Agents on Oral Disease Pathogens In Vitro

doi: 10.3390/ph15040488

Figure Lengend Snippet: The biofilm removal effect of temoporfin and KI. ( a ) The biofilm removal ability of temoporfin in oral disease pathogens under normoxic conditions. The biofilm removal efficacy of temoporfin alone and temoporfin and KI combination against ( b ) MRSA, ( c ) L. acidophilus , and ( d ) L. paracasei biofilms under hypoxic conditions. ( e ) The biofilm formation-related gene mRNA expression after MRSA was treated with vehicle and 0.125–1 μg/mL temoporfin under hypoxic conditions. ( f ) Hydrogen peroxide production of bacteria under anaerobic growth conditions. * p < 0.05 and *** p < 0.001 compared with vehicle ( a – e ) and MRSA (f). # p < 0.05 compare with each dose of temoporfin.

Article Snippet: Temoporfin (ChemScene, Monmouth Junction, NJ, USA) was dissolved in dimethyl sulfoxide (DMSO) as 100 mg/mL stock solutions and stored at −20 °C.

Techniques: Expressing, Bacteria

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Loss of SPTBN1 Suppresses Autophagy Via SETD7-mediated YAP Methylation in Hepatocellular Carcinoma Initiation and Development

doi: 10.1016/j.jcmgh.2021.10.012

Figure Lengend Snippet: Loss of SPTBN1 inhibited autophagy by activating YAP in HCC cells. A and B , QRT-PCR. Huh-7 ( A ) and PLC/PRF/5 ( B ) cells were transiently transfected with siRNA to SPTBN1 or/and YAP for 48 hours and then analyzed. YAP siRNA reversed the expression of autophagy-related genes BECN1 and ATG4B that were downregulated by SPTBN1 knockdown (n = 3; ∗ P < .05, ∗∗ P < .01 vs siCON, # P < .05, ## P < .01 vs siSPTBN1). C and D , Western blot. The decreased ratio of LC3BII/LC3B I protein was reversed by YAP siRNA in Huh-7 ( C ) and PLC/PRF/5 ( D ) cells. Significance of the mean value difference was determined using a Student t test (∗∗ P < .01 vs siCON, ## P < .01 vs siSPTBN1). E , Analysis of autophagy level by Western blot. The decreased ratio of protein LC3BII/ LC3B I was reversed by YAP inhibitor verteporfin in the Huh-7 ( upper ) and PLC/PRF/5 ( lower ) HCC cells. F , The statistical analysis of Western blot in Figure E (n = 3; ∗∗ P < .01 vs siCON, # P < .05, ## P < .01 vs siSPTBN1). G , Autophagy and autophagic flux detection by fluorescence microscopy after GFP-RFP-LC3 LV transfection and HBSS induction for 24 hours. The reduced autophagy spots in response to SPTBN1 knockdown were reversed by YAP siRNA in Huh-7 ( left ) and PLC/PRF/5 ( right ) cells. White bars represent 10 μm.

Article Snippet: Cells were also treated with the YAP inhibitor verteporfin (10 μM, APExBIO, Houston, TX) after SPTBN1 siRNA transfection.

Techniques: Quantitative RT-PCR, Transfection, Expressing, Knockdown, Western Blot, Fluorescence, Microscopy

Journal: Molecular Vision

Article Title: In vitro effects of verteporfin on ocular cells

doi:

Figure Lengend Snippet: Viability of cultured ocular cells exposed to a range of verteporfin for 24 h without exposure to laser light. The percent of live cells was determined with 3-(4,5- dimethyl-2-thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay in human scleral fibroblasts (hFibro), human trabecular meshwork cells (hTMC), and a human retinal pigment epithelial cell line (ARPE-19). Data were normalized to untreated cells (0 µg/ml verteporfin; 100% Live), and plotted as the mean (n=4) with error bars representing the standard deviation. *=p<0.05 versus 0 µg/ml verteporfin treatment.

Article Snippet: Verteporfin (Visudyne, QLT Ophthalmics Inc., Menlo Park, CA) came as a lyophilized powder of 15 mg active ingredient in approximately 765 mg of inactive ingredients.

Techniques: Cell Culture, MTT Assay, Standard Deviation

Journal: Molecular Vision

Article Title: In vitro effects of verteporfin on ocular cells

doi:

Figure Lengend Snippet: Viability of cultured ocular cells exposed to 0.5 µg/ml verteporfin with different intensities of laser light. The percent of live cells was determined with 3-(4,5- dimethyl-2-thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay in human scleral fibroblasts (hFibro), pig trabecular meshwork cells (pTMC), human trabecular meshwork cells (hTMC), and a human retinal pigment epithelial cell line (ARPE-19). Data were normalized to cells not treated with either verteporfin or laser light (0 µg/ml + 0 µJ/cm 2 ; 100% Live), and plotted as the mean (n=4) with error bars representing the standard deviation. *=p<0.05 versus both 0 µg/ml + 0 µJ/cm 2 and pretreat + 50 µJ/cm 2 .

Article Snippet: Verteporfin (Visudyne, QLT Ophthalmics Inc., Menlo Park, CA) came as a lyophilized powder of 15 mg active ingredient in approximately 765 mg of inactive ingredients.

Techniques: Cell Culture, MTT Assay, Standard Deviation